Melicia R. Gainey

ORCID: 0000-0003-0993-8284
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • Bacillus and Francisella bacterial research
  • Influenza Virus Research Studies
  • Hepatitis B Virus Studies
  • Viral Infections and Outbreaks Research
  • Monoclonal and Polyclonal Antibodies Research
  • Viral Infections and Vectors
  • Poxvirus research and outbreaks
  • interferon and immune responses
  • Advanced Biosensing Techniques and Applications
  • Protein purification and stability
  • Animal Disease Management and Epidemiology
  • Transgenic Plants and Applications
  • Immune Response and Inflammation
  • Respiratory viral infections research
  • Mosquito-borne diseases and control

Battelle
2008-2022

Influenza A viruses continue to pose a threat human health; thus, various vaccines and prophylaxis be developed. Testing of these products requires animal models including mice, guinea pigs, ferrets. However, because ferrets are naturally susceptible infection with influenza the disease state resembles that influenza, animals have been widely used as model study virus pathogenesis. In this report, statistical analysis was performed evaluate data involving 269 infected seasonal swine highly...

10.1371/journal.pone.0058337 article EN cc-by PLoS ONE 2013-03-05

The anthrax vaccine candidate AV7909 is being developed as a next generation for post-exposure prophylaxis (PEP) indication against anthrax. consists of the Anthrax Vaccine Adsorbed (AVA, BioThrax®) bulk drug substance adjuvanted with immunostimulatory oligodeoxynucleotide (ODN) compound, CPG 7909. addition 7909 to AVA enhances both magnitude and kinetics antibody responses in animals human subjects, making suitable next-generation use PEP setting. studies described here provide initial...

10.1016/j.vaccine.2017.07.076 article EN cc-by-nc-nd Vaccine 2017-07-31

Recent studies have shown the domestic ferret (Mustela putorius furo) to be a promising small animal model for study of Ebola virus (EBOV) disease and medical countermeasure evaluation. To date, most focused on traditional challenge routes, predominantly intramuscular intranasal administration. Here, we present results from non-clinical pathogenicity examining oronasal, oral, ocular mucosal routes in ferrets. Animals were challenged with 1, 10, or 100 plaque forming units EBOV followed by...

10.3390/pathogens10030292 article EN cc-by Pathogens 2021-03-04

The current global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a public health crisis with more than 168 million cases reported globally and 4.5 deaths at the time of writing. In addition to direct impact disease, economic been significant as measures contain or reduce spread have led country wide lockdowns resulting near closure many sectors economy. Antibodies are principal determinant humoral immune response infections may...

10.1371/journal.pone.0267796 article EN public-domain PLoS ONE 2022-06-03

Influenza remains a world wide health threat, thus the need for high-throughput and robust assay to quantify both seasonal avian in-fluenza A strains. Therefore, 384-well plate format was developed median tissue culture infectious dose (TCID50) utilizing detection of nucleoprotein by an in situ en-zyme linked immunosorbent (ELISA) which optimized sensitivity this assay. Highly pathogenic influenza, A/Vietnam/ 1203/04 (H5N1), interpandemic strains, A/ New Caledonia/20/99 (H1N1) A/Brisbane/...

10.4236/health.2010.21006 article EN Health 2010-01-01

The immune response to anthrax protective antigen (PA) in the non-human primate (NHP) was characterized by anti-PA IgG ELISA, toxin neutralization assay (TNA), and antibody binding kinetics affinity after vaccination challenge. NHPs were vaccinated twice with AVA or recombinant PA (rPA) vaccine administered four weeks apart aerosol challenged Bacillus anthracis Ames spores 10 post initial vaccination. Serum samples collected every two throughout challenge time periods. immunoglobulins...

10.1096/fasebj.22.2_supplement.245 article EN The FASEB Journal 2008-04-01

Background: The objective of this study was to refine a low dose ferret therapeutic model A/Vietnam/1203/04 influenza infection. Methods: Forty-four male ferrets (Mustela putorius furo), 8–15 weeks in age, were divided into 4 groups 8 (groups A, C, E and G; experimental) 3 B, D, F H; controls). Animals G challenged with 5 x 103 TCID50 via the intranasal route. Data collection staggered by group pairs A+B, C+D, E+F, G+H) so that clinical observations, blood (clinical hematology chemistry),...

10.1016/j.ijid.2010.02.372 article EN publisher-specific-oa International Journal of Infectious Diseases 2010-03-01
Coming Soon ...